Literature DB >> 30102222

[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.

Thorsten Derlin1, Sebastian Schmuck2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30102222     DOI： 10.1016/S1470-2045(18)30488-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

Review 1.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

2.  Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy.

Authors:  Friederike Völter; Lena Mittlmeier; Astrid Gosewisch; Julia Brosch-Lenz; Franz Josef Gildehaus; Mathias Johannes Zacherl; Leonie Beyer; Christian G Stief; Adrien Holzgreve; Johannes Rübenthaler; Clemens C Cyran; Guido Böning; Peter Bartenstein; Andrei Todica; Harun Ilhan
Journal:  Diagnostics (Basel)       Date:  2021-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.